

JUL 1 4 2004
U.S. PATENT & TRADEMARK OFFICE
1308

Sheet 1 of 4

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 07917-212001	Application No. 10/823,866
Information Disclosure Statement by Applicant <small>(Use several sheets if necessary)</small> <small>(37 CFR §1.98(b))</small>		Applicant Stern et al.,			
		Filing Date April 14, 2004	Group Art Unit 1632		

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/UJ/	A1	US 2003/0044389 A1	03/06/2003	Brown et al.	424	93.7	—
	A2						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes
	B1						
	B2						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/UJ/	C1	Altman et al., "Phenotypic analysis of antigen-specific T lymphocytes," <i>Science</i> 274(5284):94-96 (1996)
	C2	Baum and Staines, "MHC-derived peptides and the CD4+ T-cell repertoire: Implications for autoimmune disease," <i>Cytokines Cell Mol. Ther.</i> 3(2):115-126 (1997)
	C3	Brusic et al., "MHCPEP, a database of MHC-binding peptides: update 1997," <i>Nucleic Acids Res.</i> 26(1):368-371 (1998)
	C4	Cameron et al., "Labeling antigen-specific CD4(+) T cells with class II MHC oligomers," <i>J. Immunol. Methods</i> 268(1):51-69 (2002)
	C5	Cantrell, "T-cell antigen receptor signal transduction," <i>Immunology</i> 105(4):369-374 (2002)
	C6	Carvalho et al., "ELISPOT assay to measure antigen-specific murine CD8(+) T cell responses," <i>J. Immunol. Methods</i> 252(1-2):207-218 (2001)
	C7	Chicz et al., "Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size," <i>Nature</i> 358(6389):764-768 (1992).
	C8	Constantin et al., "Major Histocompatibility Complex (MHC) tetramer technology: an evaluation," <i>Biol. Res. Nurs.</i> 4(2):115-127 (2002)
	C9	Czerniksky et al., "A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells," <i>J. Immunol. Methods</i> 65(1-2):109-121 (1983)
	C10	Czerniksky et al., "Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-Interferon-secreting cells," <i>J. Immunol. Methods</i> 110:29-36 (1988)
	C11	Davis et al., "Ligand recognition by alpha beta T cell receptors," <i>Annu. Rev. Immunol.</i> 16:523-544 (1998)
	C12	ElGhazali et al., "Number of interleukin-4- and interferon- γ -secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation," <i>Eur. J. Immunol.</i> 23:2740-2745 (1993)
	C13	Ewen and Baca-Estrada, "Evaluation of interleukin-4 concentration by ELISA is influenced by the consumption of IL-4 by cultured cells," <i>J. Interferon Cytokine Res.</i> 21:39-43 (2001)
↓	C14	Gabrielsson et al., "Specific induction of interleukin-4-producing cells in response to <i>in vitro</i> allergen stimulation in atopic individuals," <i>Clin. Exp. Allergy</i> 27:808-815 (1997)
Examiner Signature /Unsu Jung/		Date Considered 03/27/2007

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-212001	Application No. 10/823,866
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Stern et al.,		
		Filing Date April 14, 2004	Group Art Unit 1632	
(37 CFR §1.98(b))				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/UJ/	C15	Germain, "MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation," <i>Cell</i> 76(2):287-299 (1994)
	C16	Geysen et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci. USA</i> 81(13):3998-4002 (1984)
	C17	Gorga et al., "Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line," <i>J. Biol. Chem.</i> 262(33):16087-16094 (1987)
	C18	Grey et al., "Class I MHC-peptide interactions: structural requirements and functional implications," <i>Cancer Surv.</i> 22:37-49 (1995)
	C19	Hammer et al., "HLA class II peptide binding specificity and autoimmunity," <i>Adv. Immunol.</i> 66:67-100 (1997)
	C20	Hartemann et al., "Abscence of significant Th2 response in diabetes-prone non-obese diabetic (NOD) mice," <i>Clin. Exp. Immunol.</i> 116:225-230 (1999)
	C21	Hennecke and Wiley, "T cell receptor-MHC interactions up close," <i>Cell</i> 104(1):1-4 (2001)
	C22	Huang et al., "Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG)," <i>Clin. Exp. Immunol.</i> 118:304-308 (1999)
	C23	Hunt et al., "Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry," <i>Science</i> 255(5049):1261-1263 (1992)
	C24	Janeway et al., "Appendix III. Cytokines and their receptors," <i>Immuno Biology 5, Garland Publishing</i> (2001) New York, NY pp 677 - 679
	C25	Kabilan et al., "Detection of intracellular expression and secretion of Interferon- γ at the single-cell level after activation of human T cells with tetanus toxoid <i>in vitro</i> ," <i>Eur. J. Immunol.</i> 20:1085-1089 (1990)
	C26	Kwok et al., "Use of class II tetramers for identification of CD4+ T cells," <i>J. Immunol. Methods</i> 268(1):71-81 (2002)
	C27	Lalvani et al., "Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells," <i>Lancet</i> 357:2017-2021 (2001)
	C28	Lalvani et al., "Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant <i>Plasmodium falciparum</i> malaria vaccine," <i>J. Inf. Dis.</i> 180:1656-1664 (1999)
	C29	Lalvani et al., "Rapid effector function in CD8+ memory T cells," <i>J. Exp. Med.</i> 186:859-865 (1997)
	C30	Lang et al., "A functional and structural basis for TCR cross-reactivity in multiple sclerosis," <i>Nat. Immunol.</i> 3(10):940-943 (2002)
	C31	Mashishi and Gray, "The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes," <i>Clin. Chem. Lab. Med.</i> 40(9):903-910 (2002)
	C32	Mathioudakis et al., "Multiparameter cytokine-specific affinity matrix assay for the determination of frequencies and phenotype of antigen-reactive T cells," <i>J. Immunol. Methods</i> 260(1-2):37-42 (2002)
↓	C33	Medhat et al., "Increased interleukin-4 and interleukin-5 production in response to schistosoma haematobium adult worm antigens correlates with lack of reinfection after treatment," <i>J. Infect. Dis.</i> 178:512-519 (1998)

Examiner Signature	/Unsu Jung/	Date Considered	03/29/2007
--------------------	-------------	-----------------	------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-212001	Application No. 10/823,866
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Stern et al.,	
		Filing Date April 14, 2004	Group Art Unit 1632
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/UJ/	C34	Merville et al., "Detection of single cells secreting IFN-gamma, IL-6 and IL-10 in irreversibly rejected human kidney allografts, and their modulation by IL-2 and IL-4," <i>Transplantation</i> 55:639-646 (1993)
	C35	Munk et al., "Increased numbers of interleukin-12-producing cells in human tuberculosis," <i>Infect. Immun.</i> 64:1078-1080 (1996)
	C36	Novitsky et al., "Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific Elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design," <i>J. Virol.</i> 75:9210-9228 (2001)
	C37	Olsson et al., "Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of Interferon- γ ," <i>J. Clin. Invest.</i> 86:981-985 (1990)
	C38	Özenci et al., "IL-12 ELISpot assays to detect and enumerate IL-12 secreting cells," <i>Cytokine</i> 12:1218-1224 (2000)
	C39	Perelson, "Modeling viral and immune system dynamics," <i>Nat. Rev. Immunol.</i> 2(1):28-36 (2002)
	C40	Prakken et al., "Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'," <i>Nature Medicine</i> 6(12):1406-1410 (2000)
	C41	Qian and Weiss, "T cell antigen receptor signal transduction," <i>Curr. Opin. Cell. Biol.</i> 9(2):205-212 (1997)
	C42	Reich et al., "Self peptides isolated from MHC glycoproteins of non-obese diabetic mice," <i>J. Immunol.</i> 152(5):2279-2288 (1994)
	C43	Rietz and Chen, "New B7 Family Members with Positive and Negative Costimulatory Function," <i>American J. of Transplantation</i> 4:8-14 (2004)
	C44	Robinson et al., "IMGT/HLA database--a sequence database for the human major histocompatibility complex," <i>Tissue Antigens</i> . 55(3):280-287 (2000)
	C45	Robinson et al., "IMGT/HLA Database--a sequence database for the human major histocompatibility complex," <i>Nucleic Acids Res.</i> 29(1):210-213 (2001)
	C46	Robinson et al., "IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex," <i>Nucleic Acids Res.</i> 31(1):311-314 (2003)
	C47	Rodda, "Peptide libraries for T cell epitope screening and characterization," <i>J. Immunol. Methods</i> 267(1):71-77 (2002)
	C48	Rötzscheck et al., "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348(6298):252-254 (1990)
	C49	Rudolph and Wilson, "The specificity of TCR/pMHC interaction," <i>Curr. Opin. Immunol.</i> 14(1):52-65 (2002)
	C50	Schneider et al., "A prime-boost immunization regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees," <i>Vaccine</i> 19:4595-4602 (2001)
	C51	Schwartz, "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> 71(7):1065-1068 (1992)
	C52	Soen et al., "Detection and Characterization of Cellular Immune Responses Using Peptide-MHC Microarrays," <i>PloS Biology</i> 1(3):429-438 (2003)
▼	C53	Southwood et al., "Several common HLA-DR types share largely overlapping peptide binding repertoires," <i>J. Immunol.</i> 160(7): 3363-3373 (1998)

Examiner Signature	/Unsu Jung/	Date Considered	03/29/2007
--------------------	-------------	-----------------	------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-212001	Application No. 10/823,866
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Stern et al.,		
(37 CFR §1.98(b))		Filing Date April 14, 2004	Group Art Unit 1632	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/UJ/	C54	Stern and Wiley, "The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide," <i>Cell</i> 68(3):465-477 (1992)
	C55	Taguchi et al., "Detection of individual mouse splenic T cells producing IFN- and IL-5 using the enzyme-linked immunospot (ELISPOT) assay," <i>J. Immunol. Methods</i> 128:65-73 (1990)
	C56	Van Bleek and Nathenson, "Isolation of an endogenously processed immunodominant viral peptide from the class I H-2K ^b molecule," <i>Nature</i> 348(6298):213-216 (1990)
	C57	Van Epps et al., "Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein," <i>J. Virol.</i> 73(7): 5301-5308 (1999)
	C58	Wang et al., "Induction of CD4+ T-cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine," <i>Proc. Natl. Acad. Sci. USA</i> 98:10817 (2001) pp10817 - 10822
	C59	Wucherpfennig "Structural basis of molecular mimicry," <i>J. Autoimmun.</i> 16(3): 293-302 (2001)
	C60	Xu and Sreaton, "MHC/peptide tetramer-based studies of T cell function," <i>J. Immunol. Methods</i> 268(1):21-28 (2002)
↓	C61	Zaru et al., "Cutting edge: TCR engagement and triggering in the absence of large-scale molecular segregation at the T cell-APC contact site," <i>J. Immunol.</i> 168(9):4287-4291 (2002)
	C62	

Examiner Signature /Unsu Jung/	Date Considered 03/29/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10823866	
	Filing Date		2004-04-14	
	First Named Inventor		Lawrence J. Stern	
	Art Unit		1632	
	Examiner Name			
	Attorney Docket Number		07917-212001	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/UJ/	1	20030223994	A1	2003-12-04	Hoogenboom et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T5
								<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10823866
Filing Date	2004-04-14
First Named Inventor	Lawrence J. Stem
Art Unit	1632
Examiner Name	
Attorney Docket Number	07917-212001

/UJ/	1	International Search Report and Written Opinion for International Application No. PCT/US04/11978, 6 pages (February 17, 2006)	<input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button			<input type="button" value="Add"/>
EXAMINER SIGNATURE			
Examiner Signature	/Unsu Jung/	Date Considered	03/27/2007
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.</p>			